Atara Biotherapeutics, Inc. (ATRA) EVP Sells $91,800.00 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Christopher Haqq sold 6,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $15.30, for a total value of $91,800.00. Following the completion of the transaction, the executive vice president now directly owns 349,305 shares in the company, valued at $5,344,366.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Christopher Haqq also recently made the following trade(s):

  • On Tuesday, August 15th, Christopher Haqq sold 7,604 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $14.75, for a total value of $112,159.00.
  • On Monday, July 17th, Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $14.92, for a total value of $89,520.00.

Shares of Atara Biotherapeutics, Inc. (NASDAQ ATRA) opened at 15.60 on Thursday. Atara Biotherapeutics, Inc. has a 52 week low of $11.80 and a 52 week high of $23.00. The firm has a 50-day moving average price of $14.71 and a 200-day moving average price of $15.84. The stock’s market cap is $476.72 million.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.05). On average, equities analysts anticipate that Atara Biotherapeutics, Inc. will post ($3.89) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/21/atara-biotherapeutics-inc-atra-evp-sells-91800-00-in-stock.html.

A number of equities analysts recently commented on ATRA shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, August 31st. Zacks Investment Research cut Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. ValuEngine raised Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $47.00 target price on shares of Atara Biotherapeutics in a report on Monday, September 11th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $25.50.

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRA. Redmile Group LLC raised its position in shares of Atara Biotherapeutics by 2.4% in the first quarter. Redmile Group LLC now owns 2,734,118 shares of the biotechnology company’s stock worth $56,186,000 after acquiring an additional 63,176 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Atara Biotherapeutics by 617.9% in the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after acquiring an additional 173,184 shares during the period. American International Group Inc. raised its position in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 948 shares during the period. Vident Investment Advisory LLC raised its position in shares of Atara Biotherapeutics by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 55,665 shares of the biotechnology company’s stock worth $1,144,000 after acquiring an additional 9,276 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Atara Biotherapeutics in the first quarter worth about $132,000. Institutional investors own 82.95% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply